As filed with the Securities and Exchange Commission on June 3, 2020

 

Registration Statement No. 333-               

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM S-8

 

REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933

 

 

 

 

ClearPoint Neuro, INC.

(Exact name of registrant as specified in its charter)

 

 

 

 

Delaware 58-2394628

(State or other jurisdiction

of incorporation or organization)

 

(I.R.S. Employer Identification No.)

5 Musick

Irvine, California

92618
(Address of principal executive offices) (Zip Code)

 

 

 

 

Third Amended and Restated 2013 Incentive Compensation Plan

 

(Full title of the plans)

 

 

 

  

Harold A. Hurwitz

Chief Financial Officer and Secretary

5 Musick

Irvine, California 92618

(Name and address of agent for service)

 

 

 

 

 

(949) 900-6833

(Telephone number, including area code, of agent for service) 

 

 

 

 

With copies to:

Richard F. Mattern, Esq.

Kristin C. Dunavant, Esq.

Bass, Berry & Sims PLC

100 Peabody Place, Suite 1300

Memphis, Tennessee 38103

(901) 543-5933

 

 

 

 

 

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer    Smaller reporting company
  Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

 

 CALCULATION OF REGISTRATION FEE

 

Title of securities to be registered Amount to be
registered (1)
Proposed
maximum
offering price
per share
Proposed
maximum
aggregate
offering price
Amount of
registration fee
  Common Stock, $0.01 par value per share 1,000,000 shares(2) $4.03 (3) $4,030,000 $523.09

_________________________

 

  (1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of common stock, $0.01 par value (the “Common Stock”), which become issuable under the ClearPoint Neuro, Inc. Third Amended and Restated 2013 Incentive Compensation Plan (the “Amended 2013 Plan”) by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of the Registrant’s outstanding shares of Common Stock.

 

  (2) Represents an additional 1,000,000 shares of Common Stock of the Registrant issuable under the Amended 2013 Plan.
     
  (3) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) under the Securities Act, based on the average of the high and low sales prices of the Common Stock as reported on The Nasdaq Capital Market on May 27, 2020, which was $4.03 per share.

  

 

 

REGISTRATION OF ADDITIONAL SECURITIES

This Registration Statement relates solely to the registration of additional securities of the same class as other securities for which a registration statement on this form relating to an employee benefit plan is effective. Pursuant to General Instruction E of Form S-8, this Registration Statement hereby incorporates by reference the contents of (i) the registration statement on Form S-8 filed by the Registrant with the Securities and Exchange Commission (the “Commission”) on October 25, 2013 (Registration No. 333-191908), (ii) the registration statement on Form S-8 filed by the Registrant with the Commission on August 17, 2015 (Registration No. 333-206432), and (iii) the registration statement on Form S-8 filed by the Registrant with the Commission on October 3, 2017 (Registration No. 333-220783), with respect to the ClearPoint Neuro, Inc. 2013 Incentive Compensation Plan, as amended and restated.

 

 

PART I

 

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

 

Documents containing information required by Part I of this Registration Statement will be sent or given to employees, officers, directors or others as specified by Rule 428(b)(1) under the Securities Act. In accordance with the rules and regulations of the Commission and the Note to Part I of Form S-8, such documents are not filed with the Commission either as a part of this Registration Statement or as prospectuses or prospectus supplements.

 

PART II

 

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 3. Incorporation of Documents by Reference.

 

The following documents, which have been filed by the Registrant with the Commission, are incorporated by reference into this Registration Statement:

 

  · The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 filed on March 27, 2020;

 

  · The Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020 filed on May 13, 2020;

 

  · The Registrant’s Current Reports on Form 8-K filed on January 13, 2020, January 29, 2020, February 12, 2020, April 17, 2020 and April 27, 2020; and  

 

  · The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 10 (File No. 000-54575) filed on December 28, 2011, including any subsequent amendment or any report filed for the purpose of updating such description.

 

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), prior to the filing of a post-effective amendment to this Registration Statement which indicates that all of the shares of common stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of the filing of such documents; except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current items 2.02 or 7.01 of Form 8-K that is not deemed filed under such provisions. For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

 

Under no circumstances will any information furnished under current items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Current Report on Form 8-K expressly provides to the contrary.

 

 

 

 

 

Item 8. Exhibits.

 

The exhibits listed below are filed as part of or incorporated into this Registration Statement.

 

Exhibit No.   Description
3.1   Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 11, 2012).
     
3.2   Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 8, 2015).
     
3.3   Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 26, 2016).
     
3.4   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of ClearPoint Neuro, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 12, 2020).
     
3.5   Second Amended and Restated Bylaws of ClearPoint Neuro, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 12, 2020).
     
4.1   Reference is made to Exhibits 3.1, 3.2, 3.3, 3.4 and 3.5.
     
4.2   Specimen of Common Stock Certificate of ClearPoint Neuro, Inc. (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 12, 2020).
     
4.3   Third Amended and Restated 2013 Incentive Compensation Plan (incorporated by reference to Appendix A to the Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 20, 2020).
     
5.1*   Opinion of Bass, Berry & Sims PLC
     
23.1*   Consent of Bass, Berry & Sims PLC (included in Exhibit 5.1)
     
23.2*   Consent of Cherry Bekaert LLP
     
24.1*   Power of attorney (included on signature page)
     

 

  * Filed herewith.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Irvine, state of California, on this 3rd day of June, 2020.

 

CLEARPOINT NEURO, INC.
 
By: /s/ Harold A. Hurwitz
 

Harold A. Hurwitz

Chief Financial Officer and Secretary



 

POWER OF ATTORNEY

 

The undersigned directors and officers do hereby constitute and appoint Joseph M. Burnett and Harold A. Hurwitz and each of them, with full power of substitution, our true and lawful attorneys-in-fact and agents to do any and all acts and things in our name and behalf in our capacities as directors and officers, and to execute any and all instruments for us and in our names in the capacities indicated below, that such person may deem necessary or advisable to enable the registrant to comply with the Securities Act and any rules, regulations and requirements of the Securities and Exchange Commission in connection with this registration statement, including specifically, but not limited to, power and authority to sign for us, or any of us, in the capacities indicated below, any and all amendments hereto (including pre-effective and post-effective amendments or any other registration statement filed pursuant to the provisions of Rule 462(b) under the Securities Act); and we do hereby ratify and confirm all that such person or persons shall do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

 

Signature   Title   Date

 

/s/ Joseph M. Burnett

  Chief Executive Officer and Director   June 3, 2020
Joseph M. Burnett   (Principal Executive Officer)    

 

/s/ Harold A. Hurwitz

  Chief Financial Officer   June 3, 2020
Harold A. Hurwitz   (Principal Financial and Accounting Officer)    

 

/s/ Kimble L. Jenkins

  Chairman of the Board of Directors   June 3, 2020
Kimble L. Jenkins        

 

/s/ R. John Fletcher

  Director   June 3, 2020
R. John Fletcher        

 

/s/ Pascal E.R. Girin

  Director   June 3, 2020
Pascal E.R. Girin        
         
 /s/ B. Kristine Johnson   Director   June 3, 2020
B. Kristine Johnson        
         
 /s/ Matthew B. Klein   Director   June 3, 2020
Matthew B. Klein        

 

/s/ Timothy T. Richards

  Director   June 3, 2020
Timothy T. Richards        
         
 /s/ John N. Spencer, Jr.   Director   June 3, 2020
John N. Spencer, Jr.